New drug KIVU-107 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This study tests a new drug called KIVU-107 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. The main goals are to find the safest dose and check fo…
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC